Johnson & Johnson set to revolutionize the treatment of cancer with the acquisition of Halda Therapeutics

jnj.com/media-center/press-releases/johnson-johnson-set-to-revolutionize-the-treatment-of-cancer-with-the-acquisition-of-halda-therapeutics

NEW BRUNSWICK, NJ (November 17, 2025) – Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Halda Therapeutics OpCo, Inc. (Halda), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera…

This story appeared on jnj.com, 2025-11-17 15:44:23.112000.
The Entire Business World on a Single Page. Free to Use →